Aventis Licenses Ingenuity's Products for Drug Discovery
Aventis Is Deploying Both the Ingenuity Pathways Analysis Application for Biologists and Ingenuity Pathways Knowledge Base for Bioinformaticians
Ingenuity announced that Aventis has licensed the Ingenuity Pathways Analysis application for use by its biologists to better understand the biology underlying experimental datasets. Aventis also licensed the Ingenuity Pathways Knowledge Base to enable its bioinformaticians to create proprietary systems biology solutions for internal use.
Ingenuity Pathways Analysis is a web-delivered application that enables biologists to explore, understand, and discover therapeutically relevant networks significant to their experiment results.
"The Ingenuity Pathways Knowledge Base is the world's largest manually curated biological database created from millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases," said Frank C. Mara, Senior Vice President of Ingenuity. "This product is distinctive in its unrivaled computational capabilities enabled through its highly structured ontology, unsurpassed quality of data, and genome-scale coverage. We are pleased Aventis has chosen Ingenuity."
Weitere News aus dem Ressort Wirtschaft & Finanzen
